Registro:

Referencias:

• Chomez, P., De Backer, O., Bertrand, M., De Plaen, E., Boon, T., Lucas, S., An overview of the MAGE gene family with the identification of all human members of the family (2001) Cancer Res, 61, pp. 5544-5551
• De Smet, C., Lurquin, C., Lethe, B., Martelange, V., Boon, T., DNA methylation is the primary silencing mechanism for a set of germ line-and tumor-specific genes with a CpG-rich promoter (1999) Mol Cell Biol, 19, pp. 7327-7335
• Kruit, W.H., Van Ojik, H.H., Brichard, V.G., Escudier, B., Dorval, T., Dreno, B., Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma (2005) Int J Cancer, 117, pp. 596-604
• Caballero, O.L., Chen, Y.T., Cancer/testis (CT) antigens: Potential targets for immunotherapy (2009) Cancer Sci, 100, pp. 2014-2021
• Sang, M., Wang, L., Ding, C., Zhou, X., Wang, B., Lian, Y., Melanoma-associated antigen genes-an update (2011) Cancer Lett, 302, pp. 85-90
• Laduron, S., Deplus, R., Zhou, S., Kholmanskikh, O., Godelaine, D., De Smet, C., MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription (2004) Nucleic Acids Res, 32, pp. 4340-4350
• Zhu, X., Asa, S.L., Ezzat, S., Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia (2008) Clin Cancer Res, 14, pp. 1984-1996
• Kondo, T., Zhu, X., Asa, S.L., Ezzat, S., The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer (2007) Clin Cancer Res, 13, pp. 4713-4720
• Askew, E.B., Bai, S., Hnat, A.T., Minges, J.T., Wilson, E.M., Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators (2009) J Biol Chem, 284, pp. 34793-34808
• Monte, M., Simonatto, M., Peche, L.Y., Bublik, D.R., Gobessi, S., Pierotti, M.A., MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents (2006) Proc Natl Acad Sci USA, 103, pp. 11160-11165
• Yang, B., O'Herrin, S.M., Wu, J., Reagan-Shaw, S., Ma, Y., Bhat, K.M., MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines (2007) Cancer Res, 67, pp. 9954-9962
• Marcar, L., MacLaine, N.J., Hupp, T.R., Meek, D.W., Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin (2010) Cancer Res, 70, pp. 10362-10370
• Nagao, T., Higashitsuji, H., Nonoguchi, K., Sakurai, T., Dawson, S., Mayer, R.J., MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity (2003) J Biol Chem, 278, pp. 10668-10674
• Sakurai, T., Itoh, K., Higashitsuji, H., Nagao, T., Nonoguchi, K., Chiba, T., A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells (2004) J Biol Chem, 279, pp. 15505-15514
• Peikert, T., Specks, U., Farver, C., Erzurum, S.C., Comhair, S.A., Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis (2006) Cancer Res, 66, pp. 4693-4700
• Hanahan, D., Weinberg, R.A., Hallmarks of cancer: The next generation (2011) Cell, 144, pp. 646-674
• Ferbeyre, G., De Stanchina, E., Querido, E., Baptiste, N., Prives, C., Lowe, S.W., PML is induced by oncogenic ras and promotes premature senescence (2000) Genes Dev, 14, pp. 2015-2027
• Pearson, M., Carbone, R., Sebastiani, C., Cioce, M., Fagioli, M., Saito, S., PML regulates p53 acetylation and premature senescence induced by oncogenic Ras (2000) Nature, 406, pp. 207-210
• Bernardi, R., Pandolfi, P.P., Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies (2007) Nat Rev Mol Cell Biol, 8, pp. 1006-1016
• Lallemand-Breitenbach, V., De The, H., PML nuclear bodies (2010) Cold Spring Harb Perspect Biol, 2, pp. a000661
• Fogal, V., Gostissa, M., Sandy, P., Zacchi, P., Sternsdorf, T., Jensen, K., Regulation of p53 activity in nuclear bodies by a specific PML isoform (2000) EMBO J, 19, pp. 6185-6195
• Bischof, O., Kirsh, O., Pearson, M., Itahana, K., Pelicci, P.G., Dejean, A., Deconstructing PMLinduced premature senescence (2002) EMBO J, 21, pp. 3358-3369
• Hayakawa, F., Abe, A., Kitabayashi, I., Pandolfi, P.P., Naoe, T., Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis (2008) J Biol Chem, 283, pp. 24420-24425
• Guo, A., Salomoni, P., Luo, J., Shih, A., Zhong, S., Gu, W., The function of PML in p53-dependent apoptosis (2000) Nature Cell Biol, 2, pp. 730-736
• Vousden, K.H., Prives, C., Blinded by the light: The growing complexity of p53 (2009) Cell, 137, pp. 413-431
• Reineke, E.L., Kao, H.Y., Targeting promyelocytic leukemia protein: A means to regulating PML nuclear bodies (2009) Int J Biol Sci, 5, pp. 366-376
• Nichol, J.N., Petruccelli, L.A., Miller Jr., W.H., Expanding PML's functional repertoire through post-translational mechanisms (2009) Front Biosci, 14, pp. 2293-2306
• Zhong, S., Muller, S., Ronchetti, S., Freemont, P.S., Dejean, A., Pandolfi, P.P., Role of SUMO-1-modified PML in nuclear body formation (2000) Blood, 95, pp. 2748-2752
• Drost, J., Mantovani, F., Tocco, F., Elkon, R., Comel, A., Holstege, H., BRD7 is a candidate tumour suppressor gene required for p53 function (2010) Nature Cell Biol, 12, pp. 380-389
• Simpson, A.J., Caballero, O.L., Jungbluth, A., Chen, Y.T., Old, L.J., Cancer/testis antigens, gametogenesis and cancer (2005) Nat Rev Cancer, 5, pp. 615-625
• Liuw Cheng, S., Asa, S.L., Ezzat, S., The melanoma-associated antigen A3 mediates fibronectincontrolled cancer progression and metastasis (2008) Cancer Res, 68, pp. 8104-8112
• Atanackovic, D., Hildebrandt, Y., Jadczak, A., Cao, Y., Luetkens, T., Meyer, S., Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells (2010) Haematologica, 95, pp. 785-793
• Aprelikova, O., Pandolfi, S., Tackett, S., Ferreira, M., Salnikow, K., Ward, Y., Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response (2009) Cancer Res, 69, pp. 616-624
• Suzuki, T., Yoshida, K., Wada, Y., Hamai, Y., Sentani, K., Oue, N., Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer (2007) Oncol Rep, 18, pp. 329-336
• Wu, W.S., Vallian, S., Seto, E., Yang, W.M., Edmondson, D., Roth, S., The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases (2001) Mol Cell Biol, 21, pp. 2259-2268
• Lallemand-Breitenbach, V., Zhu, J., Puvion, F., Koken, M., Honore, N., Doubeikovsky, A., Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation (2001) J Exp Med, 193, pp. 1361-1371
• Lallemand-Breitenbach, V., Jeanne, M., Benhenda, S., Nasr, R., Lei, M., Peres, L., Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway (2008) Nature Cell Biol, 10, pp. 547-555
• Doyle, J.M., Gao, J., Wang, J., Yang, M., Potts, P.R., MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases (2010) Mol Cell, 39, pp. 963-974
• Langley, E., Pearson, M., Faretta, M., Bauer, U.M., Frye, R.A., Minucci, S., Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence (2002) EMBO J, 21, pp. 2383-2396
• Bischof, O., Nacerddine, K., Dejean, A., Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways (2005) Mol Cell Biol, 25, pp. 1013-1024

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------